In 2017, Emma Childs and colleagues at the University of Chicago gave 42 healthy volunteers a capsule of THC and then put them through the Trier Social Stress Test, the standard laboratory method for making someone genuinely anxious. The group that received 7.5mg reported less distress and recovered from the stress faster. The group that received 12.5mg reported more negative mood, more subjective distress, and performed worse on the task. Same drug, same test, opposite result. Five milligrams apart.
That study is the spine of this page and the reason anxiety is different from every condition in the Pain cluster. For pain, dose determines how much benefit you get. For anxiety, dose determines whether you get benefit at all or the reverse of it. THC has a biphasic dose-response curve: low doses are anxiolytic, high doses are anxiogenic, and the effect has been documented in rodents and humans consistently enough to count as one of the better-established facts in cannabis pharmacology. The Iglesias 2023 meta-analysis of rodent work found the same shape, with anxiolytic effects clustering at low doses and anxiogenic effects at doses roughly ten times higher.
Now look at a dispensary shelf. The industry-standard serving is 10mg of THC. That number was not chosen with anxiety patients in mind. It sits above the dose that helped in the Childs trial and near the dose that made things worse, and the person who takes two because one did not seem to do much has landed decisively on the wrong side of the curve. The most common bad experience in all of cannabis, the anxious spiral after an edible, is the biphasic curve behaving exactly as the pharmacology predicts, in someone who took an ordinary product at an ordinary dose. The pharmacology did what it does. The dose was wrong.
Why the biphasic curve makes THC dosing the whole story
CB1 receptors sit in high density in the amygdala, hippocampus, and prefrontal cortex, the circuitry that generates and regulates fear. When a small amount of THC arrives, it dampens excitatory signalling in that circuit and anxiety drops. When a larger amount arrives, the effect reverses. The current mechanistic explanation involves which neurons are engaged at which concentration: low doses act preferentially on CB1 receptors on cortical glutamatergic terminals and produce calm, while higher doses recruit receptors on GABAergic neurons and produce the opposite. The details are still being worked out. The shape of the curve is not in dispute.
What makes this practically vicious is how narrow the useful window is and how badly edibles suit precision dosing. An inhaled dose can be titrated breath by breath, so someone feeling the first edge of anxiety can simply stop. An edible commits you 60 to 90 minutes before you know the answer, and the answer depends on your metabolism, whether you ate, and your tolerance. Someone who takes 10mg and starts climbing the wrong side of the curve at minute 75 has no exit. They have three more hours of it. This is where the anxiety literature and the edible format collide, and any honest page about edibles for anxiety has to say so.
Tolerance twists the curve further. Regular THC use downregulates CB1 signalling, so the dose that used to calm does less, and the intuitive fix is a bigger dose. That escalation walks toward the anxiogenic end while the person believes they are chasing the same relief they started with. Cannabis withdrawal compounds it: irritability, restlessness, and anxiety are core withdrawal symptoms, which means the anxious hours before the next dose get attributed to the underlying anxiety disorder instead of to the drug. The Sharpe 2020 critical appraisal captured the population-level version of this tension. Surveys of cannabis users report anxiety relief, while controlled human studies keep finding THC anxiogenic at higher doses. Both findings are real, and dose is what reconciles them.
What the CBD evidence actually tested
CBD is the cannabinoid with the genuine anxiolytic signal, and the research supporting it is narrower than the marketing implies in two ways that matter.
The first is the model. Bergamaschi 2011 gave 600mg of CBD to treatment-naive social phobia patients before a simulated public speaking test and brought their anxiety down to roughly the level of healthy controls, without sedation or cognitive impairment. Crippa 2011 gave 400mg and used SPECT imaging to show corresponding changes in limbic and paralimbic blood flow, which made the effect harder to dismiss as expectation. These are good studies. They test a single dose against an acute burst of social-evaluative fear in a laboratory. Generalized anxiety disorder is persistent, diffuse worry running for months. A public speaking test does not model that, and treating the two as interchangeable is the leap the CBD market makes quietly. A 2020 pharmacists' review found no published studies at all for panic disorder, specific phobia, separation anxiety, or OCD.
That began to change in 2024. Gundugurti and colleagues ran a phase 3 trial across sites in India, randomizing 178 adults with mild to moderate anxiety to 15 weeks of nanodispersible oral CBD at 300 to 600mg daily or matching placebo. It met both primary endpoints: a GAD-7 difference of 7.02 points against placebo and a HAM-A difference of 11.9 points, both at p below 0.0001, with secondary improvements in depression and sleep quality and no serious adverse events. This is the first properly powered chronic-dosing trial against a GAD-specific primary endpoint, and it is the strongest single result in the anxiety literature. It also arrives with the caveats that matter: the sponsor's employees are among the authors, it ran in one country, the effect size is larger than most SSRI trials produce, and nobody has replicated it. Treat it as the best evidence available and as a finding still waiting for independent confirmation.
The second is the dose, and here the market's error runs opposite to the THC error. CBD also follows an inverted U. Linares 2019 tested 150mg, 300mg, and 600mg in a simulated public speaking test: 300mg reduced anxiety, and 150mg and 600mg did not. Zuardi 2017 found the same shape during real-life public speaking, with 300mg outperforming both 100mg and 900mg. The peak appears to sit near 300mg in healthy volunteers, while Bergamaschi's 600mg worked in diagnosed patients, so the curve likely shifts with the population and the field has not pinned it down. The 2024 phase 3 trial settles the range from the other direction, dosing 300 to 600mg daily for fifteen weeks to reach its result. Against any of those numbers, a 25mg CBD gummy is a rounding error. The trial that gives the best evidence CBD works for anxiety used at least twelve times what a standard gummy contains, which means it is also the best evidence that the gummy will not.
The mechanism explains why CBD behaves differently from THC. CBD is a partial agonist at 5HT-1A, the serotonin receptor that buspirone targets for anxiety, and it acts as a negative allosteric modulator at CB1, dampening the receptor activity that drives THC's anxiogenic effect. That second property is the pharmacological basis for pairing them, and it is the one piece of conventional dispensary wisdom on this topic that survives contact with the evidence. CBD really does blunt THC-induced anxiety.
The protocol
Start with CBD alone and stay there for two weeks. The starting point is 25 to 50mg of CBD in the evening, understanding that this sits far below the trial doses and that the honest expectation is a modest effect. Patients who want to approach the researched range are looking at 300mg daily or more, the territory the phase 3 trial used, which is achievable with tinctures and capsules and effectively impossible with gummies at typical potencies. Cost becomes the real constraint at that point, and it is worth knowing that before spending money on a product that cannot deliver a trial-level dose at any sensible quantity.
Add THC only after CBD is established, and only in a genuinely small amount. Start at 2.5mg alongside the CBD, which puts you below the 7.5mg that worked in Childs and far below the 12.5mg that backfired. For most products this means cutting a gummy into quarters, which looks absurd and is correct. Hold at 2.5mg for at least a week before considering 5mg. Do not go past 5mg for anxiety. The curve does not reward it, and the entire point of the dosing discipline is staying on the anxiolytic side of a line most consumers cross without knowing it exists.
Keep the ratio CBD-dominant, at 10:1 or wider. The CBD does the anxiolytic work through 5HT-1A while acting as insurance at CB1 against the THC tipping the wrong way. This is the one condition in the library where a CBD-dominant ratio is unambiguously correct, and it stands in deliberate contrast to arthritis, where the human CBD trials came back null and the evidence pointed toward THC instead. The cannabinoid that fits a condition follows the biology of that condition, and anxiety and joint pain are not the same biology.
Time it in the evening and keep it consistent instead of reactive. Anxiety dosing taken as rescue medication during a spike is the pattern most likely to produce escalation, since acute distress makes a bigger dose feel justified in the exact moment when judgment about dose is worst. A steady evening dose sidesteps that. If you notice the dose creeping up, or anxiety in the gaps between doses, stop and talk to a clinician. Those are the two signatures of the tolerance and withdrawal loop.
When cannabis is the wrong tool for anxiety
Three situations deserve naming, because the anxiety market does not name them.
Anyone with a personal or family history of psychosis or schizophrenia should avoid THC. The association between high-potency THC and psychosis risk is one of the more consistent findings in the epidemiology, and the risk concentrates in exactly the people most likely to be told cannabis is a natural anxiety remedy. CBD alone does not carry this concern and has been studied in high-risk populations with a different profile entirely.
Anyone whose anxiety includes panic attacks should be careful, since THC-induced anxiety can be indistinguishable from a panic attack while lasting hours longer than one. A person with panic disorder taking a standard 10mg edible is running a real risk of an experience that reinforces the fear cycle their treatment is trying to break.
And anyone using cannabis daily to keep anxiety at bay is in the pattern this page keeps returning to. Cannabis use disorder is more common among people using it for anxiety, because the relief is real at first and the tolerance and withdrawal arrive quietly. Escalating dose and inter-dose anxiety are the two things to watch. Both mean the tool has started working against the problem it was picked up to solve.